ASH 2018 | Characterization of exceptional responders to ASCT in multiple myeloma
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
The identification of those who are likely to response to a certain therapy is invaluable. Here, Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, discusses the characterization of exceptional responders to autologous stem cell transplantation in multiple myeloma. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up